National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge

Vinod Bhatara, Michael Feil, Kimberly Hoagwood, Benedetto Vitiello, Bonnie Zima

Research output: Contribution to journalArticle

Abstract

Objectives: (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth. Methods: Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends. Results: Between 1993-94 and 1997-98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth. Conclusions: The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.

Original languageEnglish (US)
Pages (from-to)217-226
Number of pages10
JournalJournal of Attention Disorders
Volume7
Issue number4
StatePublished - May 2004
Externally publishedYes

Fingerprint

Pediatrics
Drug Therapy
Psychotropic Drugs
Safety
Growth
Antidepressive Agents
Prescriptions
Guidelines
Surveys and Questionnaires

ASJC Scopus subject areas

  • Psychology(all)

Cite this

National trends in concomitant psychotropic medication with stimulants in pediatric visits : Practice versus knowledge. / Bhatara, Vinod; Feil, Michael; Hoagwood, Kimberly; Vitiello, Benedetto; Zima, Bonnie.

In: Journal of Attention Disorders, Vol. 7, No. 4, 05.2004, p. 217-226.

Research output: Contribution to journalArticle

Bhatara, Vinod ; Feil, Michael ; Hoagwood, Kimberly ; Vitiello, Benedetto ; Zima, Bonnie. / National trends in concomitant psychotropic medication with stimulants in pediatric visits : Practice versus knowledge. In: Journal of Attention Disorders. 2004 ; Vol. 7, No. 4. pp. 217-226.
@article{8871a151d24e4bf88408e2794d0c9f41,
title = "National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge",
abstract = "Objectives: (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth. Methods: Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends. Results: Between 1993-94 and 1997-98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth. Conclusions: The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.",
author = "Vinod Bhatara and Michael Feil and Kimberly Hoagwood and Benedetto Vitiello and Bonnie Zima",
year = "2004",
month = "5",
language = "English (US)",
volume = "7",
pages = "217--226",
journal = "Journal of Attention Disorders",
issn = "1087-0547",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - National trends in concomitant psychotropic medication with stimulants in pediatric visits

T2 - Practice versus knowledge

AU - Bhatara, Vinod

AU - Feil, Michael

AU - Hoagwood, Kimberly

AU - Vitiello, Benedetto

AU - Zima, Bonnie

PY - 2004/5

Y1 - 2004/5

N2 - Objectives: (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth. Methods: Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends. Results: Between 1993-94 and 1997-98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth. Conclusions: The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.

AB - Objectives: (1) To examine U.S. national trends in the use of concomitant pharmacotherapy with the stimulant class of psychotropic drugs in youth; and (2) to present these trends in the context of (a) extant safety and efficacy data, and (b) overall trends in concomitant pharmacotherapy with psychotropic drugs for youth. Methods: Prescribing data for youths under age 18 years from National Ambulatory Medical Surveys from 1993 to 1998 were analyzed. The visits were categorized into monotherapy (only one psychotropic prescribed) and concomitant pharmacotherapy (>1 psychotropic prescribed). The proportions of these groups were computed as a percentage of all visits during which a psychotropic medication was prescribed. Differences in proportions between surveys were analyzed to determine trends. Results: Between 1993-94 and 1997-98, the proportions of visits for concomitant pharmacotherapy in association with the stimulant class increased nearly five-fold. This increase paralleled an overall increase in the proportion of visits involving prescription of more than one psychotropic medication among youth. Conclusions: The growth in concomitant pharmacotherapy with the stimulants class has out-paced the increase in safety/efficacy data to inform the use of this practice, resulting in a mismatch between trends in prescribing and growth in knowledge. A simultaneous trend of note is the overall increase in the use of concomitant pharmacotherapy with all psychotropic drugs in youth. Controlled trials are particularly needed to support commonly used combinations of stimulants with antidepressants in youth. In the absence of definitive data, clinical guidelines based on expert consensus and limited data are available and are useful.

UR - http://www.scopus.com/inward/record.url?scp=3042791262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042791262&partnerID=8YFLogxK

M3 - Article

C2 - 15487478

AN - SCOPUS:3042791262

VL - 7

SP - 217

EP - 226

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

SN - 1087-0547

IS - 4

ER -